• INmune Bio Inc INMB.OQ reported a quarterly adjusted loss of $1.05​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -50 cents. The mean expectation of six analysts for the quarter was for a loss of 38 cents per share. Wall Street expected results to range from -41 cents to -37 cents per share.

• Reported revenue was zero​; analysts expected $1.67 thousand.

• INmune Bio Inc's reported EPS for the quarter was a loss of $1.05​.

• The company reported a quarterly loss of $24.46 million.

• INmune Bio Inc shares had risen by 19.5% this quarter and lost 40.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 14.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for INmune Bio Inc is $7.00, about 60.1% above its last closing price of $2.79

This summary was machine generated from LSEG data August 8 at 04:12 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)